

Synonym

TNFRSF4,OX40,CD134,OX40L receptor,ACT35,TXGP1L

Source

Rat OX40, His Tag(OX0-R52H9) is expressed from human 293 cells (HEK293). It contains AA Val 20 - Pro 210 (Accession # P15725-1).

Predicted N-terminus: Val 20

Molecular Characterization

OX40(Val 20 - Pro 210) P15725-1

Poly-his

This protein carries a polyhistidine tag at the C-terminus

The protein has a calculated MW of 22.9 kDa. The protein migrates as 43-50 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin

Less than 1.0 EU per µg by the LAL method.

Purity

>90% as determined by SDS-PAGE.

Formulation

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

Reconstitution

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage


For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.


SDS-PAGE




Rat OX40, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 90%.

Bioactivity-ELISA

Rat OX40 / TNFRSF4 / CD134 Protein, His Tag







Immobilized Rat OX40, His Tag (Cat. No. OX0-R52H9) at 2 μ g/mL (100 μ L/well) can bind Mouse OX40 Ligand, Fc Tag (Cat. No. OXL-M526x) with a linear range of 0.2-10 ng/mL (QC tested).

Background

Tumor necrosis factor receptor superfamily member 4 (TNFRSF4) is also known as ACT35 antigen, OX40L receptor, TAX transcriptionally-activated glycoprotein 1 receptor, CD antigen CD134, OX40. OX40 / TNFRSF4 contains four TNFR-Cys repeats. TNFRSF4 is receptor for TNFSF4 / OX40L / GP34 and can interacts with TRAF2, TRAF3 and TRAF5.

Clinical and Translational Updates

Please contact us via <u>TechSupport@acrobiosystems.com</u> if you have any question on this product.